Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia

First Page		Document Content
Date: 2014-11-03 11:26:18 Organofluorides Medicine Fixed dose combination Bristol-Myers Squibb Cyclopropanes Emtricitabine/tenofovir/efavirenz Antiretroviral drug Abacavir Lamivudine Chemistry Pharmacology Gilead Sciences		Shionogi-ViiV Healthcare announces positive initial data from phase III study of dolutegravir-based regimen vs Atripla in HIV London, United Kingdom, 11 July 2012: Shionogi-ViiV Healthcare LLC today announced that initia Add to Reading List Source URL: shionogi616.tew-staging.com Download Document from Source Website File Size: 88,25 KB Share Document on Facebook

	PRESS RELEASE Particle Sciences to Develop Antiretroviral Formulations as part of MOTIF BETHLEHEM, PA- October 10, 2012 ‐ Particle Sciences, a leading drug delivery CRO, has been selected to be the formulation arm of a DocID: 1m6of - View Document
	Microsoft Word - Biographie de JF Delfraissy BIS.doc DocID: 1gw3d - View Document
	Surveillance and outbreak reports Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy C Semaille ()1, Y Le S DocID: 1gvMD - View Document
	Questioning the HIV-AIDS hypothesis: 30 years of dissent DocID: 1gtoc - View Document
	HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use FULYZAQ safely and effectively. See full prescribing information for FULYZAQ. FULYZAQ ® (crofelemer) delayed-releas DocID: 1gtlL - View Document